Novo Integrated Sciences, Inc. announced the signing of a memorandum of understanding with Boditech Med for a marketing and distribution partnership for the launch and deployment of Boditech Med's in-vitro diagnostic solutions and technology in North America. Boditech offers highly reliable in-vitro diagnostic solutions that empower clinicians and patients to improve health through quick and reliable tests, available anywhere and anytime. Along with venous blood and plasma testing, Boditech's product line includes technologies that enable accurate, thorough capillary blood tests, based on a small amount of blood from a finger prick.

Boditech also produces COVID-19 antibody and over-the-counter rapid antigen tests. Boditech recently announced plans to open a manufacturing site in Miami, Florida and is currently seeking approvals from the U.S. Food and Drug Administration for several diagnostic solutions in cardiac, cancer, hormone, infectious disease, and other therapeutic areas. Boditech intends to bring lower-cost, rapid testing that covers many critical areas of medicine, from cardiac health to cancer, to North America.